-
Enhertu's Benes Conf. for HER2+ MBC; Could Help Early Stages
Enhertu's Benefits Confirmed for Metastatic, HER2-Positive Breast Cancer; Could Help Treat Early-Stage Disease Dec 14, 2022 Updated results from the DESTINY-Breast02 and DESTINY-Breast03 studies confirmed the benefits of Enhertu for previously treated metastatic, HER2-positive breast cancer, and results from the TALENT…
-
Podcast: Experimental Capivasertib Promising for HR+, HER2- MBC
Experimental Capivasertib Seems Promising for Advanced-Stage, Hormone Receptor-Positive, HER2-Negative Breast Cancer Dec 15, 2022 Dr. Nicholas Turner explains research looking at capivasertib, a new targeted therapy medicine. Researchers are always looking for new treatments for advanced-stage breast cancer. Dr. Nicholas…
-
Podcast: What I Get From Breastcancer.org Meetups
What I Get From Breastcancer.org Meetups Dec 10, 2022 Breastcancer.org Community Member Vanessa Onsurez talks about her diagnosis, #ThisIsMBC, and Meetups. Vanessa Onsurez, who was diagnosed with metastatic breast cancer in 2021, explains the #ThisIsMBC project at the 2022 San Antonio Breast Cancer Symposium and the…
-
Paid survey
Hi! As you know, I talk highly of RC Horowitz and have been taking surveys with them since 2020. I am not employed by them. They are looking for participants for another survey. The requirements for this one are as follows: HR positive / HER2 negative NOT currently taking Hormonal/Estrogen therapy but has taken in the…
-
Podcast: Overall Survival in Enhertu vs Kadcyla for HER2+ MBC
Enhertu Offers Better Overall Survival Than Kadcyla for Metastatic HER2-Positive Breast Cancer Dec 9, 2022 Dr. Sara Hurvitz discusses new overall survival results from the DESTINY-Breast03 study. 2021 results from the DESTINY-Breast03 study showed that Enhertu (chemical name: fam-trastuzumab-deruxtecan-nxki) more than…
-
Podcast: Elacestrant Seems Effective for HR-Resistant BC
Experimental Elacestrant Seems Effective for Breast Cancer Resistant to Other Types of Hormonal Therapy Dec 8, 2022 Dr. Virginia Kaklamani explains the latest results from the EMERALD trial comparing elacestrant to the standard of care. Doctors are looking for new treatment options for people diagnosed with metastatic…
-
Podcast: What Pts Want Drs & Resrchrs to Know Abt Living W/ MBC
What Patients Want Doctors and Researchers to Know About Living With Metastatic Breast Cancer Dec 7, 2022 Metastatic breast cancer patient advocates Christine Hodgdon and Stephanie Walker explain why the viewpoints of people living with metastatic breast cancer need to be incorporated into research. A number of issues…
-
21 Years of Stage 4 MBC de novo!
Yay me! Today is the first day of my 21st year after being diagnosed with Stage 4 MBC de novo! Originally ER+, PR-, Her2+++ with liver mets. I had a recurrence in 2 chest nodes 11 years ago, which changed me to Her2- Somatic. I have had A/C, Taxotere, Gemzar, Herceptin, Aromasin, Faslodex, Kadcyla, Poziotinib, and now on…
-
Newbie Questions
Hello All! I am new here....some background. Family has history of BC. Can be traced back to my great grandmother. No genetic mutations found. Had BC first time 2006 (bilateral mastectomy with implants, salpingo oopherectomy, 3 rounds of taxol), recurrence 2013 (mastectomy redone, ACT(taxotere not taxol) DIEP Flap,…
-
A break from BCO
Dear Friends, I'd like to start by wishing you all a happy, merry everything as we approach the holidays! BCO has been a wonderful place for me over the years and I truly appreciate the support and input I have received. Some of you may be aware of the fact that over the course of 11+ years I have been the recipient of…
-
CK4/6 comparisons
Of the three CK4/6 drugs which are Kisquali, Ibrance and Verzinio is there one that is the most effective when used with letrozole? Also is there one that has fewer side effects than the others. I am anticipating that my oncologist will put me on one of these and trying to gather info to discuss my options. Thanks for any…